Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according ...
The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.
The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.